Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors

International Journal of Gynecological Pathology

Volumn 28, Issue 6, 2009, Pages 514-521

  Buza, Natalia ^a   Tavassoli, Fattaneh A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial component; Malignant mixed mullerian tumor; Mesenchymal component; P16; P53

Indexed keywords

PROTEIN P16; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CARCINOMATOSIS; CHONDROSARCOMA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM SARCOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MALIGNANT NEOPLASTIC DISEASE; MIXED MULLERIAN TUMOR; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RHABDOMYOSARCOMA; SCORING SYSTEM; SEROMA; UTERUS TUMOR; BIOSYNTHESIS; CANCER STAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; UTERUS CANCER;

AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 73949110797     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181a934e9     Document Type: Article

References (28)

1. Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed mullerian tumors of the uterus. The 1999 long course on pathology of the uterine corpus and cervix. USCAP 1999. Mod Pathol 2000;13:328-342.
2. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19.
3. McCluggage WG. Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-690
4. Mayall F, Rutty K, Campbell F, et al. P53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 1994;24:211-214
5. Wada H, Enomoto T, Fujita M, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57:5379-5385
6. Seidman JD, Chauhan S. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol 2002;22:75-82.
7. Taylor NP, Zighelboim I, Huettner PC, et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006;19:1333-1338
8. Costa MJ, Vogelsan J, Young LJ. P53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. Mod Pathol 1994;7:619-627
9. Lomo L, Nucci MR, Lee KR, et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol 2008;21:937-942
10. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecularbased classification. Virchows Arch 2004;444:213-223
11. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006;19: 1091-1100.
12. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007;26:328-333 (Pubitemid 46986071)
13. Bansal N, Herzog TJ, Seshan VE, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers. Evidence for distinct tumor behavior. Obstet Gynecol 2008;112:64-70.
14. George E, Lillemoe TJ, Twiggs LB, et al. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44.
15. McClugage WG, Haller U, Kurman RJ, et al. Mixed epithelial and mesenchymal tumours. In: Tavassoli FA, Devilee P, eds. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:245-249
16. Norris HJ, Roth E, Taylor HB. Mesenchymal tumors of the uterus. II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 1966;28:57-63.
17. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. III. A clinical and pathologic study of 31 carcinosarcomas. Cancer 1966;19:1459-1465
18. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. Am J Surg Path 1995;19:666-674
19. Ferguson SE, Tornos C, Hummer A, et al. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007;31:1653-1661
20. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39: 46-54.
21. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004;12: 1568-1578
22. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004;23: 129-137
23. Semczuk A, Jakowicki JA. Alterations of pRb1-cyclin D1- cdk4/6-p16Ink4A pathway in endometrial carcinogenesis. Cancer Lett 2004;203:1-12. (Pubitemid 37506078)
24. Semczuk A, Marzec B, Roessner A, et al. Loss of heterozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial cancer. Virchows Arch 2002;441:577-583
25. Ignatov A, Bischoff J, Schwarzenau C, et al. P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol 2008;111:365-371
26. O'Neill CJ, McCluggage WG. P16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13:8-15.
27. Ng JS, Han AC, Edelson MI, et al. Oncoprotein profiles of primary peritoneal malignant mixed mullerian tumors. Int J Gynecol Cancer 2003;13:870-874
28. Semczuk A, Skomra D, Chyzynska M, et al. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report. Pathol Res Pract 2008;204:203-207